Receive Email Updates
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
Tag Archives: IPO
Representative Goodlatte’s Innovation Act (H.R. 9) has been shelved for now, and will not receive a floor vote until September at the earlier. There is significant conflict between measures intended to deter patent trolls and the ability of non-profit institutional … Continue reading
I did not pay much attention to the fairly recent panel decision in Bristol-Myers Squibb Co. v. Teva Pharma. USA, 757 F.3d 967 (Fed. Cir. 2014). It seemed like a fairly routine panel affirmance of the district court’s finding that … Continue reading
This posting came with a set of presentation slides which you can find at the end of the post. The Industry Trilateral (of which IPO is a member) initially proposed a Common Citation Document (CCD). In response, the Trilateral have … Continue reading
Contributed by Jim Nelson, J.D., Ph.D. of Schwegman Lundberg & Woessner, P.A. The Siemens Medical Solutions USA, Inc. v. Saint-Gobain Ceramics & Plastics, Inc., (a copy is available at the end of this post) case presents a fundamental issue and … Continue reading